C-RAD AB: Agreement signed with Cablon Medical to market the C-RAD GEMini system
Press release 2013-02-25
An agreement signed with Cablon Medical to market the C-RAD GEMini system
C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The company has signed an agreement with Cablon Medical B.V, the Netherlands to market and sell the GEMini™ ED detector together with Cablon’s clinical software for portal dosimetry and imaging.
The GEMini™ ED is an advanced flat panel detector based on the Gas Electron Multiplier (GEM) technology licensed from CERN, Switzerland. Its many unique features such as dose linearity, dose rate independence and greatly improved radiation hardness makes it the only detector on the market that is fully optimized both for portal imaging, X- ray imaging and portal dosimetry applications.
C-RAD and TheraView Technology, a subsidiary of Cablon Medical BV will jointly develop a combined solution for portal imaging and dosimetry, using existing intellectual property of both companies. The combined solution will be marketed worldwide by C-RAD except for China.TheraView is getting the right to market and sell GEMini ED to customers in the Benelux countries.
Erik Hedlund, CEO, C-RAD AB:
”C-RAD is excited about the new relationship with Cablon Medical. Together with TheraView’s well-proven clinical software, C-RAD will be able to provide a superior solution for portal dosimetry and imaging. Cablon Medical will market the GEMini solution to its customers in the Benelux countries where the company has installed about one hundred systems. ”
R.A. Hooijer, President Cablon Medical BV:
“Cablon Medical is very pleased with the fact that C-RAD has chosen the TheraView´s proven software to be combined with C-RAD´s state of the art GEMini ED detector.“
About Cablon Medical BV:
Cablon Medical is a Dutch privately held company active in the medical field for more than 25 years with disciplines in radiology, oncology and dialysis.
Its subsidiary Theraview Technology develops specific modules for use in radiation therapy. Development under ISO and FDA regulations is based on the long existing TheraView EPID experience and existence in the local market since 1992 in combination with an active user group input.
About C-RAD AB
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries in Sweden; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD has own sales companies in Germany, USA and China. The headquarter of the group is located in Uppsala, Sweden. Numbers of employees are currently 22 people. The activities at C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is listed at Nasdaq Omx First North Premier. The company’s Certified Advisor is Erik Penser Bankaktiebolag.
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.com
|